<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Van, N.M.</title>
    <link>http://repub.eur.nl/res/aut/15408/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity. (Article)</title>
      <link>http://repub.eur.nl/res/pub/13522/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>Androgen insensitivity syndrome (AIS) is caused by defects in the androgen
      receptor (AR) that render the AR partially or completely inactive. As a
      result, embryonic sex differentiation is impaired. Here, we describe a
      novel mutation in the AR found in a patient with partial AIS. The mutation
      results in a substitution of a glutamine (Q) by a lysine (K) residue at
      position 902, Q902K. The AR Q902K mutation was investigated in vitro with
      respect to its functional properties. The equilibrium dissociation
      constants (K(d)s) of AR Q902K in the presence of either the synthetic
      androgen R1881 or the natural ligand DHT were slightly elevated. The R1881
      dissociation rate (t(1/2)) was increased 3-fold for AR Q902K compared with
      wild type. Transcriptional activity was decreased to 85% of wild type, and
      the dose-response curve revealed that the sensitivity to hormone was
      decreased due to the mutation. Furthermore, the 114-kDa androgen-induced
      phosphorylated AR protein band was not detectable in genital skin
      fibroblasts. However, it could be detected in transfected CHO cells
      expressing the mutant receptor in the presence of 10 and 100 nm R1881.
      Functional interaction assays and a GST pull-down assay showed that the
      interaction between the NH2 and COOH terminus of AR Q902K was reduced to
      50% of wild type. Furthermore, the transactivation by the coactivator TIF2
      (transcriptional intermediary factor 2) was decreased 2- to 3-fold. The
      half-maximal response in both assays was shifted to a higher hormone
      concentration compared with wild type. These results indicate that residue
      Q902 is involved in TIF2 and NH2/COOH interaction and that the Q to K
      mutation results in a mild impairment of AR function, which can explain
      the partial AIS phenotype of the patient.</description>
    </item>
  </channel>
</rss>